Phase 2 Study to Assess Safety, Tolerability and Efficacy of Once Weekly SC Pemziviptadil (PB1046) in Subjects With Symptomatic PAH
Clinical trial NCT03556020 · TERMINATED
Trial details
- NCT number
- NCT03556020
- Sponsor
- PhaseBio Pharmaceuticals Inc.
- Status
- TERMINATED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2018-07-15
- Primary completion
- 2022-01-07
- Enrollment
- 35
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.